J. Goldman & Co’s Pfizer PFE Stock Holding History

J. Goldman & Co’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-690,400	Closed	-$17.5M	–	597
2025 Q1	$17.5M	Buy	690,400 +393,400	+132%	+$10.3M	0.43%	73
2024 Q4	$7.88M	Buy	+297,000	New	+$8.06M	0.21%	149
2023 Q4	–	Sell	-350,000	Closed	-$11.6M	–	438
2023 Q3	$11.6M	Buy	+350,000	New	+$12.4M	0.41%	77
2020 Q4	–	Sell	-177,388	Closed	-$6.18M	–	459
2020 Q3	$6.18M	Buy	+177,388	New	+$6.22M	0.42%	78
2016 Q2	–	Sell	-158,100	Closed	-$4.45M	–	394
2016 Q1	$4.45M	Buy	+158,100	New	+$4.52M	0.28%	101
2015 Q4	–	Sell	-484,840	Closed	-$14.4M	–	285
2015 Q3	$14.4M	Buy	484,840 +431,086	+802%	+$13.8M	1.24%	15
2015 Q2	$1.71M	Buy	+53,754	New	+$1.75M	0.1%	172

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

J. Goldman & Co's PFE Position: Q2 2026 in Review

J. Goldman & Co sold out of Pfizer (PFE) in Q2 2026, closing a stake of 21,856 shares — an estimated $614K sold.

J. Goldman & Co first reported a position in PFE in Q2 2013 and held it in 11 quarters. The position peaked at $8.25M in Q4 2024. 2,827 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

J. Goldman & Co reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
J. Goldman & Co sold 21,856 Pfizer shares in Q2 2026, an estimated $614K.
J. Goldman & Co first reported a position in Pfizer in Q2 2013 and held it in 11 quarters.
J. Goldman & Co's Pfizer position peaked at $8.25M in Q4 2024.
2,827 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.